237 related articles for article (PubMed ID: 37024388)
41. Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.
Filipska M; Rosell R
Mol Oncol; 2021 Jun; 15(6):1667-1682. PubMed ID: 33969622
[TBL] [Abstract][Full Text] [Related]
42. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine.
Moldogazieva NT; Zavadskiy SP; Terentiev AA
Cancer Genomics Proteomics; 2021; 18(3 Suppl):369-383. PubMed ID: 33994362
[TBL] [Abstract][Full Text] [Related]
43. Circulating tumor DNA testing in advanced non-small cell lung cancer.
Moding EJ; Diehn M; Wakelee HA
Lung Cancer; 2018 May; 119():42-47. PubMed ID: 29656751
[TBL] [Abstract][Full Text] [Related]
44. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages.
Guibert N; Pradines A; Favre G; Mazieres J
Eur Respir Rev; 2020 Mar; 29(155):. PubMed ID: 32051167
[TBL] [Abstract][Full Text] [Related]
45. Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer.
Wang S; Li M; Zhang J; Xing P; Wu M; Meng F; Jiang F; Wang J; Bao H; Huang J; Ren B; Yu M; Qiu N; Li H; Yuan F; Zhang Z; Jia H; Lu X; Zhang S; Wang X; Xu Y; Xia W; Liu T; Xu W; Xu X; Sun M; Wu X; Shao Y; Wang Q; Dai J; Qiu M; Wang J; Zhang Q; Xu L; Shen H; Yin R
J Hematol Oncol; 2022 Oct; 15(1):137. PubMed ID: 36183093
[TBL] [Abstract][Full Text] [Related]
46. Liquid biopsy in the management of advanced lung cancer: Implementation and practical aspects.
Fernandes G; Rodrigues A; Matos C; Barata F; Cirnes L; Ferreira L; Lopes JA; Felizardo M; Fidalgo P; Brito U; Parente B
Cancer Treat Res Commun; 2023; 36():100725. PubMed ID: 37321073
[TBL] [Abstract][Full Text] [Related]
47. Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.
Heitzer E; van den Broek D; Denis MG; Hofman P; Hubank M; Mouliere F; Paz-Ares L; Schuuring E; Sültmann H; Vainer G; Verstraaten E; de Visser L; Cortinovis D
ESMO Open; 2022 Apr; 7(2):100399. PubMed ID: 35202954
[TBL] [Abstract][Full Text] [Related]
48. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review.
Krebs MG; Malapelle U; André F; Paz-Ares L; Schuler M; Thomas DM; Vainer G; Yoshino T; Rolfo C
JAMA Oncol; 2022 Dec; 8(12):1830-1839. PubMed ID: 36264554
[TBL] [Abstract][Full Text] [Related]
49. Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
Madison R; Schrock AB; Castellanos E; Gregg JP; Snider J; Ali SM; Miller VA; Singal G; Alexander BM; Venstrom JM; Chung JH
Lung Cancer; 2020 Oct; 148():69-78. PubMed ID: 32823229
[TBL] [Abstract][Full Text] [Related]
50. Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era.
Palmieri M; Frullanti E
Med Sci (Basel); 2023 Jan; 11(1):. PubMed ID: 36649045
[TBL] [Abstract][Full Text] [Related]
51. The Implication of Liquid Biopsy in the Non-small Cell Lung Cancer: Potential and Expectation.
Ren J; Liu R
Methods Mol Biol; 2023; 2695():145-163. PubMed ID: 37450117
[TBL] [Abstract][Full Text] [Related]
52. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
53. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.
Mayo-de-Las-Casas C; Garzón Ibáñez M; Jordana-Ariza N; García-Peláez B; Balada-Bel A; Villatoro S; Malapelle U; Karachaliou N; Troncone G; Rosell R; Molina-Vila MA
Expert Rev Mol Diagn; 2018 Jan; 18(1):35-45. PubMed ID: 29172773
[TBL] [Abstract][Full Text] [Related]
54. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients.
Tran LS; Pham HT; Tran VU; Tran TT; Dang AH; Le DT; Nguyen SL; Nguyen NV; Nguyen TV; Vo BT; Dao HT; Nguyen NH; Tran TH; Nguyen CV; Pham PC; Dang-Mai AT; Dinh-Nguyen TK; Phan VH; Do TT; Truong Dinh K; Do HN; Phan MD; Giang H; Nguyen HN
PLoS One; 2019; 14(12):e0226193. PubMed ID: 31841547
[TBL] [Abstract][Full Text] [Related]
55. Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial.
García-Pardo M; Czarnecka-Kujawa K; Law JH; Salvarrey AM; Fernandes R; Fan ZJ; Waddell TK; Yasufuku K; Liu G; Donahoe LL; Pierre A; Le LW; Gunasegaran T; Ghumman N; Shepherd FA; Bradbury PA; Sacher AG; Schmid S; Corke L; Feng J; Stockley T; Pal P; Rogalla P; Pipinikas C; Howarth K; Ambasager B; Mezquita L; Tsao MS; Leighl NB
JAMA Netw Open; 2023 Jul; 6(7):e2325332. PubMed ID: 37490292
[TBL] [Abstract][Full Text] [Related]
56. Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
Sands J; Li Q; Hornberger J
Lung Cancer; 2017 Aug; 110():19-25. PubMed ID: 28676213
[TBL] [Abstract][Full Text] [Related]
57. Next-generation sequencing of circulating tumor DNA for metastatic non-small cell lung cancer: a discussion on its implementation in the Brazilian clinical practice.
H Araujo L; Ferreira CG; Baldotto CS; Mathias C; Castro G; Coudry R
Future Oncol; 2021 Jan; 17(2):205-213. PubMed ID: 33052747
[TBL] [Abstract][Full Text] [Related]
58. Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives.
Yang Y; Liu H; Chen Y; Xiao N; Zheng Z; Liu H; Wan J
Cell Death Dis; 2023 Mar; 14(3):230. PubMed ID: 37002211
[TBL] [Abstract][Full Text] [Related]
59. Circulating tumor DNA as liquid biopsy in lung cancer: Biological characteristics and clinical integration.
Li C; Shao J; Li P; Feng J; Li J; Wang C
Cancer Lett; 2023 Nov; 577():216365. PubMed ID: 37634743
[TBL] [Abstract][Full Text] [Related]
60. Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
Ikushima H; Sakatani T; Usui K
Oncology; 2020; 98(1):23-28. PubMed ID: 31494653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
